El-On J, Livshin R, Even-Paz Z, Hamburger D, Weinrauch L
J Invest Dermatol. 1986 Aug;87(2):284-8. doi: 10.1111/1523-1747.ep12696697.
Sixty-seven patients, 19 females and 48 males, 4-66 years old, suffering from lesions of cutaneous leishmaniasis were treated topically with an ointment comprising 15% paromomycin sulfate and 12% methylbenzethonium chloride in white soft paraffin (P-ointment, U.K. patent GB117237A). After 10 days of treatment, twice daily, the lesions in 72% of the treated patients were free of parasites, 15% became free within an additional 20 days, without further treatment, and 13% failed to respond. Pigmentation developed in 18% of the treated lesions and inflammation of varying degree was associated with the treatment. These developments did not affect the clinical healing process which was generally completed in a period of 10-30 days after termination of treatment. In addition, 94% of the treated lesions healed with little or no scarring. No adverse clinical or laboratory side effects were observed except for a burning sensation at the site of treatment. Parasites isolated from patients who failed to respond to topical treatment were found to be susceptible to PR-MBCl in both in vitro infected macrophages and in vivo in experimentally infected BALB/c mice.
67例皮肤利什曼病患者,年龄4至66岁,其中女性19例,男性48例,采用一种软膏进行局部治疗,该软膏由白软石蜡中的15%硫酸巴龙霉素和12%氯化甲基苄乙铵组成(P软膏,英国专利GB117237A)。每天治疗两次,治疗10天后,72%的治疗患者的病灶内无寄生虫,15%在无需进一步治疗的情况下,再过20天内病灶内无寄生虫,13%治疗无效。18%的治疗病灶出现色素沉着,且治疗伴有不同程度的炎症。这些情况并未影响临床愈合过程,该过程通常在治疗结束后的10至30天内完成。此外,94%的治疗病灶愈合后几乎没有或没有疤痕。除治疗部位有烧灼感外,未观察到不良临床或实验室副作用。从对局部治疗无反应的患者中分离出的寄生虫,在体外感染的巨噬细胞和实验感染的BALB/c小鼠体内均对PR-MBCl敏感。